{
    "document_id": 251,
    "page": 22,
    "width_pt": 595.32,
    "height_pt": 841.92,
    "engine": "paddleocr_vl",
    "source_run_id": 376,
    "item_count": 10,
    "counts_by_type": {
        "footer": 2,
        "header": 2,
        "text": 6
    },
    "build_ms": 1,
    "items": [
        {
            "id": "p22.1",
            "order": 1,
            "type": "header",
            "bbox": {
                "l": 41.9915,
                "t": 800.16,
                "r": 253.149,
                "b": 784.8
            },
            "text": "Oxford University Hospitals NHS FT",
            "attrs": {
                "block_label": "header"
            }
        },
        {
            "id": "p22.2",
            "order": 2,
            "type": "header",
            "bbox": {
                "l": 456.8679,
                "t": 800.16,
                "r": 522.8546,
                "b": 785.76
            },
            "text": "TB2026.67",
            "attrs": {
                "block_label": "header"
            }
        },
        {
            "id": "p22.3",
            "order": 3,
            "type": "text",
            "bbox": {
                "l": 111.3376,
                "t": 769.92,
                "r": 525.0142,
                "b": 674.88
            },
            "text": "6.5. The “Agile” research delivery team previously part of OUH is now employed by University Hospitals Southampton as part of the Regional Research Delivery Network (RRDN) Agile team. Currently, they continue to support to a portfolio of OUH studies using Honorary Contracts with OUH, but this team with be withdrawn in August 2026 (see section 6.9)."
        },
        {
            "id": "p22.4",
            "order": 4,
            "type": "text",
            "bbox": {
                "l": 111.0976,
                "t": 668.64,
                "r": 497.6597,
                "b": 637.2
            },
            "text": "6.6. A Task & Finish Group was established in Q4 2025-26 to address three emerging risks to the clinical research delivery teams:"
        },
        {
            "id": "p22.5",
            "order": 5,
            "type": "text",
            "bbox": {
                "l": 111.3376,
                "t": 630.72,
                "r": 521.1749,
                "b": 520.32
            },
            "text": "6.7. The first priority was to. minimise the impact of reduced RDN funding.\nOUH has been awarded £8.47m in 2026-27, a reduction of 2.8% in cash terms compared to 2025-26. Funding reductions vary across delivery teams but are being mitigated through the use of R&D reserves, with staffing not expected to constrain patient study recruitment in 2026–27. It is anticipated that national policy shifts towards non-acute settings will reduce funding further in 2027–28."
        },
        {
            "id": "p22.6",
            "order": 6,
            "type": "text",
            "bbox": {
                "l": 111.0976,
                "t": 513.6,
                "r": 522.8546,
                "b": 371.28
            },
            "text": "6.8. The second priority was to manage the withdrawal of support from the Agile team, employed by the RRDN, which will be deploying them to support research delivery in non-acute settings in the future. The affected studies have been mapped to best-fit OUH delivery teams and the work has been absorbed within existing capacity. The only exception is surgical oncology, which requires a new team and the business case for this has been approved by TME. The posts in this team will be funded by the block funding provided to OUH by the RDN, for delivering NIHR portfolio research."
        },
        {
            "id": "p22.7",
            "order": 7,
            "type": "text",
            "bbox": {
                "l": 111.3376,
                "t": 365.28,
                "r": 525.2541,
                "b": 254.64
            },
            "text": "6.9. The third priority is to develop a proposal to restructure the clinical research delivery workforce to ensure clear lines of reporting and accountability of the 38 teams delivering research at OUH. The current arrangements are complex (~40% staff employed by OU), limiting flexibility, responsiveness and efficiency. In this regard, OUH remains an outlier and this complexity presents ongoing operational and assurance risks."
        },
        {
            "id": "p22.8",
            "order": 8,
            "type": "text",
            "bbox": {
                "l": 111.5775,
                "t": 247.92,
                "r": 525.2541,
                "b": 89.04
            },
            "text": "6.10. We are developing a career pathway for clinical research delivery staff and have implemented generic job descriptions for consistency and capabilities. Engagement with the workforce is achieved through the Lead NMAHPs Clinical Research Delivery (CRD) Forum for senior staff and the NMAHPs CRD network group for more junior staff. Ongoing workstreams include creating SOPs with an electronic system to track compliance, developing a bi-monthly induction programme and short modules on My Learning Hub, and enhancing advanced practice roles in clinical research delivery. Further details are available in the Appendix."
        },
        {
            "id": "p22.9",
            "order": 9,
            "type": "footer",
            "bbox": {
                "l": 41.5116,
                "t": 50.4,
                "r": 401.919,
                "b": 36.72
            },
            "text": "Research & Development Governance and Performance Report 2025-26",
            "attrs": {
                "block_label": "footer"
            }
        },
        {
            "id": "p22.10",
            "order": 10,
            "type": "footer",
            "bbox": {
                "l": 451.349,
                "t": 50.16,
                "r": 523.3345,
                "b": 36.72
            },
            "text": "Page 22 of 38",
            "attrs": {
                "block_label": "number"
            }
        }
    ]
}